Mylan Inc (NASDAQ:MYL)
| 31.28 Data as of May 20 |  -0.12 / -0.38%Today’s Change | 20.50 Today|||52-Week Range 31.89 | +13.95% Year-to-Date |
Latest MYL News | Press Releases
| Actavis: What it's like to join the Fortune 500 May 10 / Fortune | Valeant Misses Earnings and Revenue Estimate in 1Q (Revised) - Analyst Blog May 07 / Zacks.com |
| Women CEOs in the Fortune 500 May 09 / Fortune |
Today’s Trading
| Previous close | 31.40 |
| Today’s open | 31.35 |
| Day’s range | 31.14 - 31.89 |
| Volume | 4,321,381 |
| Average volume (3 months) | 6,208,071 |
| Market cap | $12.0B |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/20/2013
Growth & Valuation
| Earnings growth (last year) | +24.59% |
| Earnings growth (this year) | +10.78% |
| Earnings growth (next 5 years) | +10.00% |
| Revenue growth (last year) | +11.49% |
| P/E ratio | 20.9 |
| Price/Sales | 1.67 |
| Price/Book | 3.71 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PRGOPerrigo Co | -0.45 | -0.38% |
| FRXForest Laboratories ... | -0.55 | -1.43% |
| BMRNBioMarin Pharmaceuti... | -1.58 | -2.47% |
| ACTActavis Inc | +1.65 | +1.31% |
Data as of 4:00pm ET, 05/20/2013
Financials
| Next reporting date | July 31, 2013 |
| EPS forecast (this quarter) | $0.67 |
| Annual revenue (last year) | $6.8B |
| Annual profit (last year) | $640.9M |
| Net profit margin | 9.37% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Generic |
Chief Executive Officer & Director Heather M. Bresch, MBA |
President & Director Rajiv Malik, MBA |
Corporate headquarters Canonsburg, Pennsylvania |
Forecasts
